The drug’s principal inventor, Michael Sofia, founded OnCore with a sales executive from Pharmasset
Inc., where Sovaldi originated. At ContraVir Pharmaceuticals
Inc. and Chimerix Inc., the leadership ranks are similarly peppered with Gilead and Pharmasset alumni.
“We’re gunning for a cure,” Sofia said in an interview. “With Sovaldi, we clearly brought innovation with the drug’s discovery and getting it to market. We feel we can translate that experience to hep B.